anyone else exhausted by the sema reformulation hype cycle

Every six months it's a new "semaglutide is being reformulated" or "oral sema breakthrough" headline. The actual rate of meaningful new clinical data on semaglutide has been moderate but steady, not the dramatic acceleration the headlines suggest.

The Phase 3 SOUL cardiovascular outcomes trial in T2D with CV disease + CKD is the meaningful next readout. Not the marketing cycle stuff.